Learn More
Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non-Hodgkin's lymphoma(More)
The paper describes a generic tool that generates automatically natural language presentations of proofs from various automated and interactive deductive systems. Proofs from diierent sources are translated into a uniied format and equipped with a block structure. These proofs can be easily combined. Several proof transformation procedures, based only on(More)